Cantor Fitzgerald Maintains Overweight on Elevance Health, Lowers Price Target to $485
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald has maintained an Overweight rating on Elevance Health but lowered its price target from $600 to $485.
October 18, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Elevance Health but lowered its price target from $600 to $485, indicating a more cautious outlook.
The lowering of the price target from $600 to $485 suggests a less optimistic view on Elevance Health's future performance, which could lead to a short-term negative impact on the stock price. However, the Overweight rating indicates that the analyst still sees potential for the stock to outperform the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100